Brokerages predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will post ($0.33) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The highest EPS estimate is ($0.23) and the lowest is ($0.43). Oxford Immunotec Global reported earnings of ($0.22) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 50%. The business is expected to report its next earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full-year earnings of ($2.11) per share for the current financial year, with EPS estimates ranging from ($2.22) to ($2.00). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.25) to ($0.75). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Oxford Immunotec Global.

Several research analysts recently commented on the company. Cowen reiterated a “buy” rating and issued a $19.00 price target on shares of Oxford Immunotec Global in a research report on Thursday, September 28th. BTIG Research assumed coverage on Oxford Immunotec Global in a research report on Thursday, September 28th. They set a “buy” rating and a $21.00 target price for the company. Zacks Investment Research upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. ValuEngine lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Tuesday, October 31st. Finally, Robert W. Baird restated a “buy” rating and set a $20.00 target price on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $19.75.

Oxford Immunotec Global (OXFD) traded down $0.20 on Thursday, reaching $14.59. The company had a trading volume of 392,816 shares, compared to its average volume of 111,740. Oxford Immunotec Global has a 12 month low of $12.19 and a 12 month high of $19.51. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.38.

In related news, CEO Peter Wrighton-Smith sold 55,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the transaction, the director now directly owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The disclosure for this sale can be found here. 8.11% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of the company. Parkwood LLC increased its position in shares of Oxford Immunotec Global by 12.9% during the second quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after purchasing an additional 1,465 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Oxford Immunotec Global by 8.8% during the second quarter. The Manufacturers Life Insurance Company now owns 18,631 shares of the company’s stock valued at $313,000 after buying an additional 1,500 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Oxford Immunotec Global by 16.0% during the second quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock valued at $224,000 after buying an additional 1,845 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Oxford Immunotec Global by 9.1% during the second quarter. Rhumbline Advisers now owns 24,500 shares of the company’s stock valued at $412,000 after buying an additional 2,053 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Oxford Immunotec Global by 5.4% during the second quarter. Vanguard Group Inc. now owns 69,043 shares of the company’s stock valued at $1,161,000 after buying an additional 3,507 shares during the last quarter. 89.35% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Post Earnings of -$0.33 Per Share” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/12/05/zacks-analysts-anticipate-oxford-immunotec-global-plc-oxfd-will-post-earnings-of-0-33-per-share.html.

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.